<p>在過去三個月中，4 位分析師對 Afya（納斯達克：AFYA）發佈了評級，提供了從看漲到看跌的多樣化觀點。</p>
<p>下表快速概述了他們最近的評級，突出了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析師最近對 Afya 進行了評估，並提供了 12 個月的價格目標。平均目標為 18.0 美元，最高預估為 22.00 美元，最低預估為 16.00 美元。當前平均價格目標較之前的 19.75 美元下降了 8.86%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770987658_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="價格目標圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770987658_0.png"/></p>
<h2>解讀分析師評級：深入分析</h2>
<p>對最近分析師行動的深入分析揭示了金融專家對 Afya 的看法。以下總結概述了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mauricio Cepeda</td>
<td>摩根士丹利</td>
<td>下調</td>
<td>低於大盤</td>
<td>$16.00</td>
<td>$17.50</td>
</tr>
<tr>
<td>Andre Salles</td>
<td>瑞銀</td>
<td>下調</td>
<td>中性</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Andre Salles</td>
<td>瑞銀</td>
<td>下調</td>
<td>買入</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Marcelo Santos</td>
<td>摩根大通</td>
<td>下調</td>
<td>中性</td>
<td>$22.00</td>
<td>$24.50</td>
</tr>
</tbody>
</table>
<h3>關鍵見解：</h3>
<ul>
<li><strong>採取的行動：</strong> 針對市場動態和公司表現的變化，分析師更新他們的建議。無論是 “維持”、“上調” 還是 “下調” 他們的立場，都表明他們對與 Afya 相關的最新發展的反應。這為分析師對公司當前狀態的看法提供了洞察。</li>
<li><strong>評級：</strong> 分析趨勢時，分析師提供定性評估，範圍從 “跑贏大盤” 到 “跑輸大盤”。這些評級傳達了對 Afya 相對於更廣泛市場的表現預期。</li>
<li><strong>價格目標：</strong> 理解預測，分析師提供對 Afya 未來價值的估計。檢查當前和之前的目標為分析師變化的預期提供了洞察。</li>
</ul>
<p>通過理解這些分析師評估及相關財務指標，捕捉 Afya 市場地位的寶貴見解。保持信息靈通，並通過我們的評級表做出戰略決策。</p>
<p>隨時瞭解 Afya 分析師評級。</p>
<p>如果您對跟蹤小型股新聞和表現感興趣，您可以從這裏開始跟蹤。</p>
<h2>關於 Afya</h2>
<p>Afya Ltd 是一家總部位於巴西的醫學教育集團。其教育組合除了醫學外，還包括管理、牙科、法律、工程、護理、心理學和會計科學等多個課程。它有三個業務板塊；本科生通過與醫學院相關的本科課程提供教育服務，本科健康科學和其他前健康本科項目，繼續教育提供醫學教育、專業化和醫學研究生課程，通過數字和麪對面的內容進行授課；醫療實踐解決方案為醫生提供臨牀決策、臨牀管理和醫患關係，併為醫療參與者提供訪問、需求和效率。</p>
<h3>Afya 的經濟影響：分析</h3>
<p><strong>市值分析：</strong> 公司的市值低於行業基準，反映出與同行相比規模的縮小。這種定位可能受到增長預期或運營能力等因素的影響。</p>
<p><strong>收入增長：</strong> Afya 在過去三個月的表現顯著。截至 2025 年 9 月 30 日，公司實現了 <strong>10.38%</strong> 的令人印象深刻的收入增長率。這標誌着公司頂線收益的顯著增加。與競爭對手相比，公司面臨困難，增長率低於消費品行業同行的平均水平。</p>
<p><strong>淨利潤率：</strong> Afya 的淨利潤率超過行業標準，突顯了公司的卓越財務表現。公司以 <strong>16.71%</strong> 的淨利潤率有效管理成本，實現強勁盈利。</p>
<p><strong>股本回報率（ROE）：</strong> Afya 的 ROE 低於行業平均水平，表明在有效利用股本方面可能面臨挑戰。ROE 為 <strong>3.32%</strong>，公司在實現最佳財務回報方面可能面臨障礙。</p>
<p><strong>資產回報率（ROA）：</strong> Afya 的 ROA 低於行業標準，指向在有效利用資產方面的困難。ROA 為 <strong>1.68%</strong>，公司可能在從其資產中提供令人滿意的回報方面遇到挑戰。</p>
<p><strong>債務管理：</strong> Afya 的債務與股本比率為 <strong>0.63</strong>，低於行業平均水平，反映出對債務融資的依賴較低，採取了更為保守的財務策略。</p>
<h2>分析師評級是如何確定的？</h2>
<p>銀行和金融系統的專家，分析師專注於特定股票或定義行業的報告。他們的全面研究包括參加公司電話會議和會議，分析財務報表，並與內部人士互動，以生成所謂的股票分析師評級。通常，分析師每季度評估和評級每隻股票一次。</p>
<p>分析師可以通過納入增長預估、收益和收入等指標的預測來增強他們的評估，為投資者提供額外的指導。重要的是要承認，儘管分析師在股票和行業方面是專家，但他們是人類，在提供見解時會表達他們的觀點。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>

AFYA

<p>在過去三個月中，四位分析師對 Afya（NASDAQ:AFYA）進行了評級，顯示出從看漲到看跌的情緒混合。12 個月的平均目標價為 18.00 美元，低於 19.75 美元，最高為 22.00 美元，最低為 16.00 美元。分析師們調整了他們的評級，一些人因市場動態而下調了目標價。Afya 是一家巴西醫學教育集團，顯示出 10.38% 的收入增長率，但在股本回報率和資產回報率方面面臨挑戰。其債務與股本比率低於行業平均水平，表明其採取了保守的財務策略</p>

<p>In the last three months, 4 analysts have published ratings on Afya (NASDAQ: AFYA), offering a diverse range of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>在過去三個月中，4 位分析師對 Afya（納斯達克：AFYA）發佈了評級，提供了從看漲到看跌的多樣化觀點。</p>
</div><p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表快速概述了他們最近的評級，突出了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts have recently evaluated Afya and provided 12-month price targets. The average target is $18.0, accompanied by a high estimate of $22.00 and a low estimate of $16.00. Experiencing a 8.86% decline, the current average is now lower than the previous average price target of $19.75.</p>
<div class="lb-trans"><p>分析師最近對 Afya 進行了評估，並提供了 12 個月的價格目標。平均目標為 18.0 美元，最高預估為 22.00 美元，最低預估為 16.00 美元。當前平均價格目標較之前的 19.75 美元下降了 8.86%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770987658_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1770987658_0.png"/></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<div class="lb-trans"><h2>解讀分析師評級：深入分析</h2>
</div><p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Afya. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>對最近分析師行動的深入分析揭示了金融專家對 Afya 的看法。以下總結概述了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mauricio Cepeda</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$16.00</td>
<td>$17.50</td>
</tr>
<tr>
<td>Andre Salles</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Andre Salles</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Marcelo Santos</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$24.50</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mauricio Cepeda</td>
<td>摩根士丹利</td>
<td>下調</td>
<td>低於大盤</td>
<td>$16.00</td>
<td>$17.50</td>
</tr>
<tr>
<td>Andre Salles</td>
<td>瑞銀</td>
<td>下調</td>
<td>中性</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Andre Salles</td>
<td>瑞銀</td>
<td>下調</td>
<td>買入</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Marcelo Santos</td>
<td>摩根大通</td>
<td>下調</td>
<td>中性</td>
<td>$22.00</td>
<td>$24.50</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵見解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Afya. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Afya compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Afya's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>採取的行動：</strong> 針對市場動態和公司表現的變化，分析師更新他們的建議。無論是 “維持”、“上調” 還是 “下調” 他們的立場，都表明他們對與 Afya 相關的最新發展的反應。這為分析師對公司當前狀態的看法提供了洞察。</li>
<li><strong>評級：</strong> 分析趨勢時，分析師提供定性評估，範圍從 “跑贏大盤” 到 “跑輸大盤”。這些評級傳達了對 Afya 相對於更廣泛市場的表現預期。</li>
<li><strong>價格目標：</strong> 理解預測，分析師提供對 Afya 未來價值的估計。檢查當前和之前的目標為分析師變化的預期提供了洞察。</li>
</ul>
</div><p>Capture valuable insights into Afya's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<div class="lb-trans"><p>通過理解這些分析師評估及相關財務指標，捕捉 Afya 市場地位的寶貴見解。保持信息靈通，並通過我們的評級表做出戰略決策。</p>
</div><p>Stay up to date on Afya analyst ratings.</p>
<div class="lb-trans"><p>隨時瞭解 Afya 分析師評級。</p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您對跟蹤小型股新聞和表現感興趣，您可以從這裏開始跟蹤。</p>
</div><h2>About Afya</h2>
<div class="lb-trans"><h2>關於 Afya</h2>
</div><p>Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.</p>
<div class="lb-trans"><p>Afya Ltd 是一家總部位於巴西的醫學教育集團。其教育組合除了醫學外，還包括管理、牙科、法律、工程、護理、心理學和會計科學等多個課程。它有三個業務板塊；本科生通過與醫學院相關的本科課程提供教育服務，本科健康科學和其他前健康本科項目，繼續教育提供醫學教育、專業化和醫學研究生課程，通過數字和麪對面的內容進行授課；醫療實踐解決方案為醫生提供臨牀決策、臨牀管理和醫患關係，併為醫療參與者提供訪問、需求和效率。</p>
</div><h3>Afya's Economic Impact: An Analysis</h3>
<div class="lb-trans"><h3>Afya 的經濟影響：分析</h3>
</div><p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 公司的市值低於行業基準，反映出與同行相比規模的縮小。這種定位可能受到增長預期或運營能力等因素的影響。</p>
</div><p><strong>Revenue Growth:</strong> Afya's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of <strong>10.38%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<div class="lb-trans"><p><strong>收入增長：</strong> Afya 在過去三個月的表現顯著。截至 2025 年 9 月 30 日，公司實現了 <strong>10.38%</strong> 的令人印象深刻的收入增長率。這標誌着公司頂線收益的顯著增加。與競爭對手相比，公司面臨困難，增長率低於消費品行業同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Afya's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>16.71%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> Afya 的淨利潤率超過行業標準，突顯了公司的卓越財務表現。公司以 <strong>16.71%</strong> 的淨利潤率有效管理成本，實現強勁盈利。</p>
</div><p><strong>Return on Equity (ROE):</strong> Afya's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>3.32%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> Afya 的 ROE 低於行業平均水平，表明在有效利用股本方面可能面臨挑戰。ROE 為 <strong>3.32%</strong>，公司在實現最佳財務回報方面可能面臨障礙。</p>
</div><p><strong>Return on Assets (ROA):</strong> Afya's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>1.68%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> Afya 的 ROA 低於行業標準，指向在有效利用資產方面的困難。ROA 為 <strong>1.68%</strong>，公司可能在從其資產中提供令人滿意的回報方面遇到挑戰。</p>
</div><p><strong>Debt Management:</strong> Afya's debt-to-equity ratio is below the industry average at <strong>0.63</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> Afya 的債務與股本比率為 <strong>0.63</strong>，低於行業平均水平，反映出對債務融資的依賴較低，採取了更為保守的財務策略。</p>
</div><h2>How Are Analyst Ratings Determined?</h2>
<div class="lb-trans"><h2>分析師評級是如何確定的？</h2>
</div><p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<div class="lb-trans"><p>銀行和金融系統的專家，分析師專注於特定股票或定義行業的報告。他們的全面研究包括參加公司電話會議和會議，分析財務報表，並與內部人士互動，以生成所謂的股票分析師評級。通常，分析師每季度評估和評級每隻股票一次。</p>
</div><p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<div class="lb-trans"><p>分析師可以通過納入增長預估、收益和收入等指標的預測來增強他們的評估，為投資者提供額外的指導。重要的是要承認，儘管分析師在股票和行業方面是專家，但他們是人類，在提供見解時會表達他們的觀點。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>
</div>

深入分析 Afya 股票：分析師的觀點（4 個評級）